PPARGC1A and neoplasm: This observation was in agreement with reports that therapeutic intervention in BRAF-mutant melanoma induces a PGC1A-driven shift from glycolysis to increased oxidative phosphorylation for improved reactive oxygen species (ROS) detoxification, thus conferring chemoresistance to the tumor cells [43,47,48].